Radiopharmaceuticals: Brookline Capital initiates Buy rating, $18 PT.

Radiopharmaceuticals: Brookline Capital initiates Buy rating, $18 PT.

Brookline Capital Markets has initiated coverage on Radiopharm Theranostics (NASDAQ: RADX) with a Buy rating and a price target of $18.00. The clinical-stage pharmaceutical company, currently trading at $4.43 with a market cap of $33.83M, has analyst targets ranging from $12.24 to $30.46 [1].

Radiopharm Theranostics is developing a pipeline of radiopharmaceutical candidates, with seven programs primarily in preclinical or Phase 1 stages. The company's most advanced candidate, RAD101, is a novel imaging agent for brain metastases currently in Phase 2b trials. Data from the first two cohorts are expected in the third quarter of 2025 [1].

Brookline Capital noted that several additional studies should produce early readouts in the second half of 2025, and the company has sufficient cash to fund operations until June 2026. Additionally, Buy-rated Lantheus (NASDAQ: LNTH) Holdings owns 12% of Radiopharm Theranostics stock, providing financial and other support, which Brookline Capital suggests presents potential for an acquisition in the future [1].

In other recent news, Radiopharm Theranostics announced it has received a $4.5 million research and development tax incentive from Australia’s R&D Tax Incentive program. This financial support is intended for companies conducting eligible research and development activities in Australia. ThinkEquity has also initiated coverage on Radiopharm Theranostics with a Buy rating and a price target of $15, reflecting confidence in the company’s growth potential [1].

References:
[1] https://www.investing.com/news/analyst-ratings/radiopharm-theranostics-stock-initiated-with-buy-rating-at-brookline-capital-93CH-4143875